Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Silexion Therapeutics is a clinical-stage biotech specializing in RNA interference therapies targeting KRAS-driven cancers, notably pancreatic cancer. Its lead candidate, SIL204, aims to silence mutant KRAS genes using intratumoral delivery, with a focus on locally advanced pancreatic tumors. The company develops personalized, targeted treatments to improve survival outcomes, leveraging proprietary technology and strategic collaborations in oncology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.